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Abstract 
In drug development, it is important to evaluate drug exposure, since efficacy and 
safety of a drug are related to drug exposure. Based on this concept, equivalency of drug 
exposure is used for demonstrating therapeutic equivalence of different formulations in 
bioequivalence (BE) studies, and drug-drug interaction (DDI) studies are conducted to 
know an effect of a co-administered drug on drug exposure of a test drug. Thus, to know 
factors affecting drug exposure is useful for efficient clinical development. In this 
research, factors affecting intra-subject variability of drug exposure and factors relating 
to effect of acid-reducing agents (ARAs) on drug exposure were investigated. 
First, we investigated factors affecting intra-subject variability of drug exposure, 
which affect the results of BE studies focusing on two factors: absolute oral 
bioavailability (BA) and acidic nature of drugs. The relationship between absolute oral 
BA and intra-subject variability of drug exposure (Cmax and AUC) showed negative 
log-linear relationship in the BE studies of 65 orally-administered immediate-release 
drugs under fasted condition. Drugs with poor absolute oral BA less than 5% showed 
high intra-subject CV in the range of 30%-65%. In contrast, drugs with high absolute 
oral BA more than 80% showed low intra-subject CV less than 20%. Also, acidic drugs 
with pKa < 6 had higher intra-subject CV of Cmax than AUC compared to other types 
of drugs. The intra-subject CV ratios of Cmax to AUC for acidic drugs with pKa < 6 
were significantly higher than those for other types of drugs. 
Second, we investigated factors relating to an effect of acid-reducing agents (ARAs) 
on drug exposure. Twenty-nine DDI study results with ARAs were selected and the 
relationships between the effect of ARAs on Cmax or AUC ratio (with/without ARA) 
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and potential factors influencing drug exposure such as dose number 
(dose/250/solubility at neutral pH) and solubility ratio (acidic/neutral pH) were 
investigated. The effect of ARAs on the Cmax or AUC ratio decreased with the 
increasing value of both factors, but the solubility ratio was a more appropriate predictor 
for the effect of ARAs on drug exposure.  
For factors affecting intra-subject variability of drug exposure, it would be efficient to 
take different strategies based on absolute oral BA values. If absolute oral BA is < 5%, 
high intra-subject CV is expected so that applying replicate crossover design and 
two-stage BE is recommended to mitigate a risk of BE failure. If absolute oral BA is > 
80%, low intra-subject CV is expected, so estimating sample size by assuming the 
intra-subject CV of 20% would be efficient. In addition, it is recommended to confirm 
whether a test drug is acidic compound with pKa < 6 when planning a BE study. ARAs 
may affect drug exposure for orally-administered drugs exhibiting pH dependent 
solubility. Since solubility ratio of acidic pH to neutral pH was found to be a good 
predictor to estimate the effect of ARA on drug exposure, investigating solubility at 
acidic and neutral pH is proposed in early stage of drug development. And it is 
recommended considering necessity and timing for a dedicated DDI study with ARAs 
based on the predicted effect of ARAs on drug exposure. 
The factors affecting drug exposure investigated in this research are useful for 
establishing an appropriate study design and determining necessity and timing of 
clinical studies. Thus, our findings can contribute to efficient clinical development of 
orally-administered drugs in the future.  
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1. Introduction 
 
In drug development, drug exposure such as Cmax and AUC is evaluated in most 
clinical studies, and exposure-efficacy and -safety relationships are explored to select 
clinical dose to optimize benefit/risk balance. It is based on the concept that drug 
exposure is thought to be related to efficacy and safety of drugs (Figure 1).  
 
Figure 1  Relationship between drug exposure and efficacy or safety response 
During clinical development for orally-administered drugs, drug formulations are 
commonly changed; capsule formulation used in a first-in-human study, for example, is 
changed to tablet formulation as a final market formulation. Sometimes formulation or 
manufacturing process of investigational drugs used for pivotal trials is changed in 
order to prepare smaller formulation for being easy to swallow or to increase 
manufacturing scale. When formulations are proposed to be changed, a bioequivalence 
(BE) study is conducted to demonstrate similarity of drug exposure between test and 
reference formulations. In BE studies, based on the concept that drug exposure is related 
to efficacy and safety of the drug, similarity of drug exposure between different 
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formulations is examined for ensuring therapeutic equivalency. In BE studies, it is 
required that 90% confidence intervals (CIs) of test/reference ratio for Cmax and AUC 
following drug administration fall within 80.00-125.00 percent. The 90% CI of 
test/reference ratio is determined by the point estimate (i.e. true ratio), number of 
subjects and the degree of intra-subject variability. It is useful to know the degree of 
intra-subject variability for drug exposure before conducting a BE study, because 
intra-subject variability is one of the major determinants for sample size estimation of a 
BE study and it is well-known that a risk of BE failure increases with the increasing 
intra-subject variability. In addition, for drugs having high intra-subject variability, there 
are some counterplans provided by health authorities to mitigate a risk of BE failures. 
Therefore, we investigated factors affecting intra-subject variability of drug exposure 
based on BE study results. 
In drug-drug interaction (DDI) studies, the effect of a co-administered drug on drug 
exposure of a test drug is evaluated by variables of Cmax and AUC following the 
administration of a test drug alone or combination with a co-administered drug. It is 
important to assess factors affecting drug exposure in early clinical development, 
because there is a possibility that they may affect efficacy and safety results in pivotal 
clinical trials. Thus, knowledge of potential factors affecting drug exposure is useful for 
securing safety of patients enrolled in clinical studies and for constructing appropriate 
study design by managing those factors in clinical development. Also, it is important to 
describe the factors affecting PK in package insert to provide appropriate information 
about precautions to clinicians, pharmacists and patients. A DDI study with 
acid-reducing agents (ARAs) is one of DDI studies to assess the effect of gastric pH 
elevation on PK for a test drug. In recent years, the DDI study with ARAs is interested 
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especially in molecularly targeted anti-cancer drug development. However, there are 
few reports investigating predictors for the effect of ARAs on drug exposure. Thus, we 
investigated it based on DDI study results for orally-administered drugs with or without 
ARAs under fasted condition.  
   
Recently, drug development cost is getting bigger and bigger, and efficient development 
is highly desirable by establishing appropriate clinical trial design and by skipping 
unnecessary clinical trials. Thus, we conducted the present study to investigate factors 
affecting drug exposure for orally-administered drugs, focusing on BE studies and DDI 
studies with ARAs.  
This thesis consists of the following two studies: 
1. Investigation of factors affecting intra-subject variability of Cmax and AUC for 
orally-administered drugs 
2. Investigation of factors affecting Cmax and AUC for orally-administered drugs 
with or without ARAs. 
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2. Part I: Factors affecting intra-subject variability of drug 
exposure 
 
2.1. Introduction 
BE studies are used for assessing equivalency of drug exposure between a test and a 
reference product. It is thought that the PK equivalency secures therapeutic equivalency, 
because drug exposure is related to efficacy and safety of test drugs. Studies to establish 
BE between two products are important for formulation or manufacturing changes 
occurring during drug development and post-approval stages, in addition to registration 
of generic drug products. Regulatory requirements for BE are different between 
countries, but generally it is required that 90% CIs of test/reference ratio for Cmax and 
AUC following drug administration fall within 80.00-125.00 percent. The 90% CI of 
test/reference ratio is affected by the point estimate (i.e. true ratio), number of subjects 
and the degree of intra-subject variability. 
For highly variable drug (HVD) products, defined as those for which intra-subject CV 
in Cmax and AUC is 30% or greater, a large number of subjects are needed to 
demonstrate BE, because high intra-subject CV extends the range of the CI. Tanguay et 
al. [1] examined over 1200 BE studies and observed that the failure rate increased with 
the increase of intra-subject variability, reaching 85% when intra-subject CV was 
greater than 35%. To avoid unnecessary human testing, the European Medicines Agency 
(EMA) and the U.S. Food and Drug Administration (FDA) proposed a reference-scaled 
BE method for HVD products [2]. However, in this case, replicated crossover design is 
required to know the extent of intra-subject variability for a reference product. Canadian, 
Japanese and European BE guidelines allow to add subjects and to perform a pooled 
statistical analysis in case of an inconclusive outcome after an initial group of subjects 
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to increase the power of the study when pre-defined in the protocol [3]. However, this 
add-on subject study would have enormous impact on cost and timeline for drug 
development. Thus, it would be useful to know the extent of intra-subject variability for 
drug exposure before conducting a BE study. In the present study, we investigated 
factors affecting intra-subject variability of drug exposure based on BE study results 
following single oral administration of immediate-release drug products under fasted 
condition. We focused on two factors: absolute oral BA and acidic nature of drugs. 
The first factor is the absolute oral BA. Davit et al. [4] reported that approximately 60% 
of HVD products were highly variable mainly due to drug substance characteristics. 
And it is considered that extensive first-pass metabolism and poor absorption are major 
factors contributing to high variability. Since both extensive first-pass metabolism and 
poor absorption are related to absolute oral BA, we investigated whether there is a 
relationship between the degree of intra-subject variability and absolute oral BA for our 
first objective in this study. 
The second factor is acidic nature of drugs. We have observed that intra-subject CV of 
Cmax is considerably higher than that of AUC in acidic drugs. We thought that Cmax of 
acidic drugs is susceptible to gastrointestinal pH based on the simulation by Tsume et al. 
[5]. They simulated drug dissolution and absorption with variation in intestinal pH for 
BCS class 2 weak acidic drugs, and showed that gastrointestinal pH had enormous 
impact on the dissolution and the oral absorption. The value of Cmax was reduced with 
lowering gastrointestinal pH, while the AUC showed marginal change. It is because 
BCS class 2 weak acidic drugs act like BCS class 1 compound in the small intestine at 
neutral pH. For variability of physiological pH, Dressman et al. [6] reported that gastric 
pH in healthy subjects under fasted condition was fluctuating and elevated gastric pH 
6 
 
(pH above 4) was observed for average 7 min during the 60 min pH monitoring. If this 
elevated gastric pH occurs just after oral administration of acidic drugs, it would result 
in increasing the rate of dissolution of acidic drugs due to its pH-dependent solubility 
and, hence, lead to an increase in the rate of absorption, Cmax. Consequently, 
fluctuation of gastric pH under fasted condition would lead to an increase in 
intra-subject variability of Cmax for acidic drugs. Thus, we investigated whether acidic 
drugs have higher intra-subject CV of Cmax as compared to that of AUC. 
Based on these hypotheses, we conducted the present study with the aim of 
investigating factors affecting intra-subject variability of drug exposure, focusing on 
absolute oral BA and acidic nature of drugs. 
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2.2. Method 
Literature search 
To obtain BE study results of immediate-release drug products after single oral 
administration under fasted condition, PubMed literature search was performed in 
2008-2014 with the following terms: included “bioequivalence, crossover, single, 
healthy and blood” and NOT included “extended”. Then, inappropriate articles such as 
not fasting BE studies, not oral administration, and no parent drug PK data were 
excluded. BE data of metabolites were inappropriate for this study because metabolism 
is an additional factor of variability as compared to a parent drug and absolute oral BA 
is calculated based on AUC of a parent drug. Drugs having absolute oral BA, which was 
obtained from US package insert (Drugs@FDA [7]), were used for our first objective.  
Also, for our second objective, test drugs were classified into four types (acidic with 
pKa <6, acidic with pKa ≥ 6, basic and zwitterionic drugs) based on functional group in 
its structure and pKa values. Predicted pKa values of drugs were used from 
chemicalize.org by ChemAxon [10]. Acidic drugs were separated by the pKa value of 6, 
because dissolution rate of acidic drugs with pKa <6 would be more sensitive to pH 
change in gastrointestinal tract following oral administration of drugs. Three neutral 
drugs were removed from the dataset due to limited number of drugs.  
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Estimation of intra-subject variability  
To estimate intra-subject CV of Cmax and AUC, residual variance was estimated from 
the number of subjects and 90% CIs, which were obtained from each BE study by the 
following equation: 
90%CI = EXP(Diff ± t0.05,N-2 *SQRT(s2*2/N)), 
where Diff represents the difference between the test and reference means of the 
logarithmically transformed metric mT and mR, s2 is the residual (within-subject) 
variance of the logarithmically transformed characteristics [calculated as the mean 
square error (MSE) of analysis of variance (ANOVA)], and N is the number of 
participants in the BE study. 
Then the residual variance was converted to intra-subject CV by the following equation: 
Intra-subject CV = SQRT(EXP(s2)-1) . 
The estimated intra-subject CV values were consistent with the observed data that were 
calculated in some articles tested in our study (data not shown). When one compound 
has multiple intra-subject CV values, the geometric mean was calculated for the 
subsequent analysis. 
Absolute oral BA 
Absolute oral BA was obtained from US package insert (Drugs@FDA). If only 
minimum to maximum data is available, the arithmetic mean value was calculated. For 
clopidogrel and mycophenolate mofetil, which have extremely poor oral BA, the 
absolute oral BA was calculated by using AUC values following intravenous 
administration from articles [8, 9]. For calculation of absolute oral BA, dose-normalized 
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oral AUC values were divided by dose-normalized intravenous AUC values as follows: 
Absolute oral BA (%) = (AUC oral / Dose oral) / (AUC intravenous / Dose intravenous) x 100 
Statistical analysis 
Relationships between absolute oral BA and intra-subject CV of Cmax and AUC were 
analyzed by log-linear regression. Relationships of intra-subject CV between Cmax and 
AUC separated by drug type were analyzed by simple linear regression. Intra-subject 
CV ratios of Cmax to AUC were compared between four types of drugs (acidic with 
pKa < 6, acidic with pKa ≥ 6, basic and zwitterionic drugs) using the Student’s t-test 
(significance level of 0.0083, Bonferroni correction) using StatsDirect (ver 2.7.9; 
StatsDirect Ltd, Altrincham, Cheshire, UK). 
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2.3. Result 
In the present study, 1) relationships between intra-subject CV and absolute oral BA, 
and 2) relationships between intra-subject CV of Cmax and AUC classified by drug type 
were investigated based on the articles obtained through the literature search. Figure 2 
shows the flowchart of the literature search in the study. 
Based on the PubMed search as shown in section 2.2, 65 drugs with 129 articles were 
selected as Dataset 1. Table 1 shows the list of compounds for Dataset 1 with absolute 
oral BA, which are represented in parenthesis. Also, 137 drugs with 235 articles were 
selected as Dataset 2 and classified into 4 types based on functional group and pKa 
values as acidic (pKa < 6), acidic (pKa ≥ 6), basic and zwitterionic drugs. Table 2 
shows the list of acidic drugs with pKa < 6 selected from Dataset 2, with acidic 
functional group, pKa and intra-subject CV values. 
Figure 3 shows the relationship between absolute oral BA and intra-subject CV of AUC 
and Cmax based on the data from Dataset 1. Intra-subject CV increased with a decrease 
in absolute oral BA. When absolute oral BE was less than 5%, the intra-subject CV 
values ranged from 30% to 48% for AUC and 30% to 65% for Cmax, which are 
regarded as HVD products in BE guidelines. On the other hand, when absolute oral BE 
was more than 80%, the intra-subject CV values of Cmax and AUC were less than 20%, 
except for one case (moxifloxacin: CV of Cmax was 28%). Relationship between oral 
BA and intra-subject CV showed negative correlation. The R2 values in the log-linear 
regression for AUC and Cmax were 0.703 and 0.517, respectively.  
Figure 4 shows the relationship of intra-subject CV between Cmax and AUC by acidity. 
Each type of drugs showed linear positive correlation with R2 values ranging from 
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0.626 to 0.763. Acidic drugs with pKa < 6 showed the highest slope of the regression 
line (approximately 2.52) and slopes for other types of drugs ranged from 0.75 to 1.15. 
Mean ± standard deviation values for intra-subject CV ratios of Cmax to AUC were 
2.00 ± 0.64 for acidic drugs with pKa < 6, 1.41 ± 0.59 for acidic drugs with pKa ≥ 6, 
1.41 ± 0.50 for basic drugs and 1.38 ± 0.59 for zwitterionic drugs. Figure 5 shows 
box-and-wisker plot for each type of drugs. The ratio for acidic drugs with pKa < 6 was 
significantly higher than that for any other types with P values less than 0.0083. 
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Figure 2  Flowchart of the Literature Search for this study 
BA: bioavailability, BE: bioequivalence, PK: pharmacokinetics 
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Table 1  List of drugs with absolute oral BA in Dataset 1 
Drug Name aBA Drug Name aBA Drug Name aBA 
Abacavir 85 Ethinylestradiol 55 Nateglinide 73 
Alendronate 0.62 Finasteride 63 Nevirapine 93 
Aliskiren 2.5 Gabapentin 60 Ondansetron 56 
Ambroxol 75 Hydrochlorothiazide 71 Pitavastatin 51 
Amlodipine 77 Ibandronate 0.6 Pregabalin 90 
Atomoxetin 78.5 Imatinib 98 Ramipril 28 
Atorvastatin 14 Irbesartan 70 Repaglinide 56 
Azithromycin 38 Ketorolac 100 Risperidone 70 
Bisoprolol 80 Lamivudine 86 Rosiglitazone 99 
Bosentan 50 Lamotrigine 98 Rosuvastatin 20 
Cefdinir 18.5 Levetriacetam 100 Saquinavir 4 
Ciprofloxacin 70 Levofloxacin 99 Sildenafil 41 
Clonidine 75 Losartan 33 Sirolimus 17.8 
Clopidogrel 0.208* Lovastatin 5 Stavudine 86.4 
Cyclobenzaprin 44 Meloxicam 89 Tacrolimus 18 
Darunavir 37 Metformin 55 Tizanidine 40 
Diclofenac 50 Metoclopramide 80 Tramadol 75 
Digoxin 70 Mirtazapine 50 Trospium 9.6 
Drospirenone 80.5 Montelukast 64 Valproate 100 
Erlotinib 60 Moxifloxacin 90 Valsartan 25 
Eplerenone 69 Mycophenolate mofetil 0.502* Zidovudine 64 
Escitalopram 80 Naproxen 95   
Values in parenthesis represent absolute oral BA (%). 
aBA: absolute oral BA 
* Absolute oral BA was calculated by dividing dose-normalized AUC oral by 
dose-normalized AUC intravenous; AUC oral was derived from literature used in Dataset 1 
and AUC intravenous was derived from literatures for clopidogrel [8] and mycophenolate 
mofetil [9], respectively. 
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Table 2  List of acidic drugs with pKa less than 6 in Dataset 2 
Drug name Acidic functional pKa a) Intra-subject CV(%) b) 
 group  Cmax AUC Ratio (Cmax/AUC) 
Aceclofenac carboxylic acid 3.4 25 10 2.4 
Artesunate carboxylic acid 3.8 58 19 3.1 
Atorvastatin carboxylic acid 4.3 32 15 2.2 
Bosentan sulfonamide 5.8 39 17 2.3 
Diclofenac carboxylic acid 4.0 39 16 2.5 
Flurbiprofen carboxylic acid 4.4 15 9 1.7 
Glimepiride sulfonylurea 4.3 14 11 1.3 
Ibuprofen carboxylic acid 4.9 21 6 3.3 
Isotretinoin carboxylic acid 5.0 9 7 1.3 
Ketorolac carboxylic acid 3.8 19 8 2.4 
Naproxen carboxylic acid 4.2 12 6 1.9 
Nateglinide carboxylic acid 4.0 17 9 1.8 
Probenecid carboxylic acid 3.5 17 10 1.7 
Rosuvastatin carboxylic acid 4.0 22 17 1.3 
Triflusal carboxylic acid 3.4 17 12 1.4 
Valproic acid carboxylic acid 5.1 15 11 1.4 
a) Predicted values derived from ChemAxon website (http://www.chemicalize.org/) [10] 
b) Intra-subject CV was estimated in this study (Methods section) 
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Figure 3  Relationship between absolute oral BA and intrasubject CV of AUC or 
Cmax 
Open circle (○, n=65) and triangle (∆, n=65) represent data for intrasubject CV of AUC 
and Cmax, respectively. Dotted line shows log-linear regression between absolute oral 
BA and intrasubject CV. The regression equation and coefficient of determination (R2) 
are shown in the box. 
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Figure 4  Relationship of intrasubject CV between Cmax and AUC by acidity 
[acidic (pKa < 6 and pKa ≥ 6), basic and zwitterionic drugs] 
Open diamond (N=16), square (N=20), triangle (N=38) and circle (N=63) represent 
acidic drug with pKa <6, acidic drug with pKa ≥ 6, basic drug and zwitterion drug, 
respectively. Dotted line shows simple linear regression of intrasubject CV between 
Cmax and AUC. The regression equation and coefficient of determination (R2) are 
shown in the box. 
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Figure 5  Box-and-whisker plot for ratio of intra-subject CV of Cmax to AUC by 
drug types 
*: Statistically significant difference observed after Bonferroni correction (p < 0.0083) 
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2.4. Discussion 
In the present study, we investigated factors affecting intra-subject variability of drug 
exposure: absolute oral BA and acidic nature of drugs. The relationship between 
absolute oral BA and intra-subject variability of drug exposure (Cmax or AUC) showed 
roughly log-linear negative correlation (Figure 3) and the intra-subject variability 
increased with a decrease in absolute oral BA. Concerning the difference of 
intra-subject variability between acidic drugs and other types of drugs, the values of 
intra-subject CV ratios of Cmax to AUC for acidic drugs were significantly higher than 
those for other types. 
Davit et al. [4] reviewed over 1000 BE studies of 180 different drugs evaluated by 
FDA’s Office of Generic Drugs (OGD) during 2003-2005, of which 31% were highly 
variable for Cmax or AUC. Approximately 60% of the HVDs were due to drug 
substance pharmacokinetic characteristics, and formulation performance contributed to 
the high variability for only about 20% of the total. They also studied drug substance 
characteristics contributing to high variability and addressed that 83% (29 out of 35 
drugs) of HVDs were subject to extensive first-pass metabolism and the others were of 
low aqueous solubility (skeletal muscle relaxant), acid labile (reverse transcriptase 
inhibitor), and low oral BA (bisphosphonates). Since low aqueous solubility leads to 
poor oral absorption and bisphosphonates are known to be poor oral absorption due to 
their very low lipophilicity and ionized form at physiological pH [11], it is considered 
that poor absorption is another major factor contributing to high variability. After oral 
administration of drug products, systemic drug exposure is affected by absorption and 
first-pass metabolism. Thus, it is thought that absolute oral BA, which is derived from 
fraction of absorption and fraction of availability passing pre-systemic metabolism, 
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seems one of the major factors affecting the extent of intra-subject variability.  
As shown in Figure 3, intra-subject CV of AUC and Cmax increased with a decrease in 
absolute oral BA. As far as we know, this is the first research that systematically 
investigates the relationship between absolute oral BA and intra-subject variability of 
drug exposure. The relationship between intra-subject CV and absolute oral BA are 
characterized by log-linear regression. In our results the R2 value for AUC was higher 
than that for Cmax. It would be reasonable, since absolute oral BA values are calculated 
based on AUC values from oral and intravenous administration. 
In drug development, a relative or formal BE study is occasionally required without 
prior information of intra-subject CV. Based on our results, intra-subject CV of AUC 
and Cmax were generally less than 20% when absolute oral BA is more than 80%. To 
facilitate drug development for drugs with high absolute oral BA, it would be one of the 
options to plan a BE study setting 20% for intra-subject CV of sample size estimation, 
without doing a pilot study for assessing intra-subject CV. In contrast, when absolute 
oral BA is less than 5%, intra-subject CV showed more than 30%, which is regarded as 
HVDs. Thus, for drugs with low absolute oral BA, it is better to plan a BE study with 
replicated crossover design. Also, two-stage BE approach, which needs to describe the 
possibility of adding subjects in the protocol based on the first BE test, would be useful 
to mitigate a risk of failure from the first BE test. 
We also examined whether acidic nature of drugs tend to be affiliated with much higher 
intra-subject variability of Cmax as compared to that of AUC. The slope of intra-subject 
CV of Cmax to that of AUC for acidic drugs with pKa < 6 showed 2.52, which is higher 
than other types of drugs (Figure 4). In general, intra-subject CV of Cmax is slightly 
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higher than that of AUC, since it would be difficult to obtain true Cmax values in 
clinical studies. However, the relatively high slope for acidic drug with pKa <6 cannot 
be explained only by general difference of intra-subject CV between Cmax and AUC. It 
was further confirmed by investigating intra-subject CV data derived from other acidic 
drugs of which pKa is less than 6: acetylsalicylic acid (intra-subject CV 24% for Cmax, 
18% for AUC [12]), captopril (31% for Cmax, 16% for AUC [12]), furosemide (60% 
for Cmax, 22% for AUC [12]), gemfibrozil (32% for Cmax, 12% for AUC [12]), 
glibenclamide (22% for Cmax, 14% for AUC [13]) and mefenamic acid (48% for Cmax, 
15% for AUC [14]). These additional data were consistent with the results in Figure 
3-a).  
Considering that acidic drugs with pKa < 6 have much higher intra-subject CV of Cmax 
than that of AUC, we also tested whether the R2 value for the relationship between 
absolute oral BA and intra-subject CV of Cmax from Dataset 1 is improved when data 
from such drugs are excluded. The R2 value was increased from 0.517 to 0.560 when 
the data from atorvastatin, bosentan, diclofenac, ketorolac, naproxen, nateglinide and 
valproate were excluded. 
Generally, acidic drugs having carboxyl group such as non-steroidal anti-inflammatory 
drugs (NSAIDs) have poor solubility at low pH and high solubility at neutral pH, which 
depends on fraction of ionic form of a compound. This pH-dependent solubility has also 
an impact on dissolution profile of drug products. Tsume et al. [5] simulated drug 
dissolution and absorption for BCS class 2 weak acidic drugs (ibuprofen and 
ketoprofen) when gastrointestinal pH is lowered. Gastrointestinal pH had enormous 
impact on the dissolution and, hence, the oral absorption of ibuprofen. When the pH 
was lowered by 2.0 compared with the average physiological pH range in human (pH 
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6.0-7.4), the value of Cmax was reduced by 58.1%, while the AUC showed marginal 
change. The reason why AUC showed marginal change is because BCS class 2 weak 
acidic drugs act like BCS class 1 drug in the small intestine at neutral pH. Rinaki et al. 
[15] also suggested that BCS classification of NSAIDs, most of which are acidic drugs 
with extensive absorption, move from Class 2 to Class 1 as pH increases from 1.2 to 7.4, 
by using a quantitative version of BCS. 
Dressman et al. [6] investigated gastric pH in healthy subjects under fasted condition. 
Their data indicated that the gastric pH was fluctuating and elevated to higher values 
(pH above 4) in most subjects (average duration, 7 ± 6 min during 60 min monitoring). 
Therefore, there is a possibility that solubility of acidic drugs is elevated at increased pH 
and its absorption rate increases when the elevation of pH occurs close to the timing of 
drug administration. Since it is thought that increased pH occurs unexpectedly, this then 
leads to an increase in variation of drug exposure, especially in Cmax based on 
pH-dependent solubility of acidic drugs  
In fact, BE study results from enteric-coated tablets of diclofenac, which is an acidic 
drug with pKa 4.0, showed that the intra-subject CV of Cmax and AUC were estimated 
to be 13% and 13%, respectively [16]. In contrast, intra-subject CV values for 
immediate-release tablets of diclofenac in this study were 39% and 16% for Cmax and 
AUC, respectively. In enteric-coated formulation, impact of gastric pH fluctuation 
would be masked because dissolution occurred only at higher pH range in 
gastrointestinal tract. These observations indicate that enteric-coated formulation has a 
potential to reduce intra-subject CV of Cmax for acidic drugs as compared to 
immediate-release formulation. 
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Extensions for biowaivers of BCS class 2 compounds are under discussion based on 
simulation results from several groups [15, 17, 18, 19]. Generally they argued that some 
BCS class 2 acidic drugs are justified to be subject to a biowaiver, because these drugs 
can dissolve quickly and behave like BCS class 1 drugs at intestinal pH (6.5-7.0) in the 
gastrointestinal tract, even though they exhibit low solubility at acidic pH. However, our 
results indicated that acidic drugs tend to have much higher intra-subject CV of Cmax 
than AUC. Thus, impact of Cmax variability on efficacy and safety has to be assured 
when considering extension for biowaiver of BCS class 2 acidic drugs. 
To investigate relationship between intra-subject CV and absolute oral BA without other 
influential factors, BE results under fed condition and those with controlled-release drug 
products were excluded from this study. However, some extent of variability for 
intra-subject CV still remains especially in Cmax even if drugs have similar absolute 
oral BA. This variability would be due to formulation effect of immediate-release drug 
products (e.g. variability of dissolution), dose-dependency on absolute oral BA (i.e. 
non-linear pharmacokinetics), physiological factors like gastric emptying, and assay 
variability for quantification of drug concentration. To improve predictability of 
intra-subject variability, further investigation is needed with consideration for these 
factors. 
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3. Part II: Factors affecting drug exposure with or without ARAs 
 
3.1. Introduction 
There are three types of acid-reducing agents (ARAs) based on the mechanism of 
action: antacids, histamine H2-receptor antagonists (H2 blockers), and proton pump 
inhibitors (PPIs). Antacids such as magnesium hydroxide exert their effects by directly 
neutralizing gastric acid, resulting in a quick onset and a short duration of suppression 
on gastric acid production. H2 blockers compete reversibly with histamine at the H2 
receptors in the gastric parietal cells, leading to reduced gastric acid production. On the 
other hand, PPIs inactivate the proton pump (i.e., the gastric H+, K+-ATPase) at the 
secretory surface of the gastric parietal cells by irreversibly binding to the pump, 
resulting in suppression of gastric acid production. [20]. It was reported that ARAs were 
frequently administered to HIV patients (approximately 37% of the patients) and cancer 
patients (approximately 20%-33% of the patients) [21, 22]. 
A DDI study with acid-reducing agents (ARAs) is one of DDI studies to assess the 
effect of gastric pH elevation on PK of a test drug. For a drug having pH-dependent 
solubility, elevation of gastric pH by ARAs would affect fraction of ionized form and 
dissolution in gastrointestinal tract. Therefore, elevation of gastric pH may affect its 
absorption, leading to change of drug exposure. 
In 2012 Budha et al. [23] reported that most molecular targeted anticancer drugs are 
weak bases that exhibit pH-dependent solubility, and suppression of gastric acidity with 
ARAs could impair their absorption and may lead to consequent reduction in efficacy. 
After this publication, health authorities have become liable to raise a question whether 
ARAs affect drug exposure of a test drug with pH-dependent solubility. And health 
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authorities request a dedicated DDI study with ARAs for molecularly targeted 
anti-cancer basic drugs having pH-dependent solubility at the post-marketing stage. 
However, some drugs (cabozantinib, crizotinib etc) did not show decrease of drug 
exposure when co-administered with ARAs in dedicated DDI studies conducted 
post-market, even if the test drug is a weak basic drug with pH-dependent solubility. 
So far, few reports have been published in which factors affecting drug exposure with or 
without ARAs were investigated. Zhang et al. [20] investigated orally-administered 19 
basic drugs selected from US package insert regarding effect of ARAs on PK and 
physicochemical properties. They proposed a preliminary conceptual framework 
whether or not a dedicated DDI study with ARAs for a test drug should be considered, if 
a test drug meets all of the following conditions: 1) basic drug, 2) pH-dependent 
solubility, 3) if clinical dose divided by water volume (250 mL), which is a general 
volume to receive an orally-administered drug, is higher than the solubility of a test 
drug at neutral pH. Based on their research, approximately 16% and 52% of test drugs 
were false positive when the criteria of positive ARA effect was defined as 25% and 
50% decrease of drug exposure, respectively. Considering relatively high false positive 
rate (~50%) in the proposed framework, it would be desirable to find more appropriate 
factors affecting drug exposure following oral drug administration with or without 
ARAs. 
To find more appropriate factors affecting drug exposure with or without ARAs, we 
investigated the relationship between effect of ARA on drug exposure and ratios of 
solubility at acidic pH to that at neutral pH as well as dose number used for the previous 
research.  
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3.2. Method 
 
Selection of clinical data 
PubMed literature search was performed from 2007 to 2015 Sep based on the following 
terms: (a) “acid reducing agent” or “proton pump inhibitor” or “H2 blocker”, (b) “effect” 
or “influence” or “drug interaction”, (c) “human” or “clinical study”, and (d) 
“pharmacokinetics”. Further it was confirmed whether there are clinical results for DDI 
with ARAs available from US package inserts to obtain the results for anti-cancer drugs 
as much as possible, since DDI with ARAs has attracted attention in oncology drug 
development. 
Some PPIs and H2 blockers are known to be substrates and inhibitors for CYP2C19 and 
organic cation transporter 2 (OCT2), respectively. Thus, if DDI studies with ARAs were 
conducted to assess drug interaction via CYP enzymes and transporters, those clinical 
data were excluded. 
 
Physicochemical properties 
For the selected drugs, information on physicochemical properties for solubility at 
acidic and neutral pH, pKa, BCS class and acidity was obtained from the publication, 
FDA review report and Japanese interview form for each drug. 
 
Relationship between effect of ARAs on drug exposure and physicochemical 
properties 
Effect of ARAs on drug exposure was evaluated by exposure ratios (AUC or Cmax 
values with ARAs divided by those without ARAs). When one compound has multiple 
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results from more than one clinical DDI studies, arithmetic mean for the exposure ratios 
was calculated for the subsequent analysis. 
The relationship between physicochemical properties and exposure ratios were 
investigated. We examined mainly the following two variables as potential factors 
related to exposure ratios: 
1. Dose number = dose tested in clinical study (mg) / 250 (mL) / solubility at 
neutral pH (mg/mL) 
2. Solubility ratio = solubility at acidic pH (mg/mL) / solubility at neutral pH 
(mg/mL) 
We assumed that the pH range of solubility at acidic and neutral pH were generally 1-2 
and 5-7, respectively, based on the consideration for normal gastric pH under fasted 
condition and elevated gastric pH following ARAs under fasted condition. 
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3.3. Result 
Selection of clinical data 
Totally 29 DDI study results from 24 drugs with solubility data were obtained (Figure 
6), which included 17 drugs co-administered with PPIs and 12 drugs co-administered 
with H2 blockers. Most of them were basic drugs. Summarized data of the drugs were 
listed in Table 3.  
Since clopidogrel is a substrate of CYP2C19, most clinical data obtained under the 
condition co-administered with PPIs were excluded. However, the DDI study results of 
clopidogrel co-administered with rabeprazole was not excluded, because rabeprazole is 
thought to be a very weak CYP2C19 inhibitor [24, 25]. Cimetidine (H2 blocker) is 
known to be a substrate and an inhibitor for organic cation transporter 2 (OCT2) [26], 
and the DDI study results with cimetidine via OCT2 were excluded.  
Gabapentin is freely soluble in water as well as in both basic and acidic aqueous 
solutions, so the solubility ratio was regarded as 1. The solubility of GSK1349572 does 
not change over the physiological pH range [27], so the solubility ratio was regarded as 
1. The solubility data for imatinib shows that it is freely soluble (100-1,000 mg/mL) up 
to pH 5.5 and its pKa is 7.7, so the solubility ratio was regarded as 1. The solubility of 
indinavir is pH-dependent, being greater than 100 mg/mL at pH 3.0 and smaller than 
0.03 mg/mL at pH 6.0. So the solubility ratio was regarded as 3333. Although the acidic 
pH of pH 3 is slightly higher than normal gastric pH of pH 1-2, the solubility at pH 1-2 
is thought to be similar to that at pH 3 since the pKa value is 6.2. Since the solubility 
data for nilotinib shows that it is slightly soluble (1-10 mg/mL) at pH 1.0, very slightly 
soluble (0.1-1 mg/mL) at pH 2.0 and pH 3.0, and practically insoluble (<0.1 mg/mL) in 
buffer solutions of pH ≥ 4.5, the solubility ratio was regarded as 100 (10 mg/mL divided 
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by 0.1 mg/mL). Since revexepride has high solubility across the gastric pH range, effect 
on its PK due to a change in gastric pH is unlikely [28]. Thus, the solubility ratio was 
regarded as 1. 
  
Relationship between Cmax or AUC ratios and dose number 
In the previous research by Zhang et al. [20], dose number at neutral pH was proposed 
to be used as one of the criterion for selecting drugs for which the sponsor should 
consider conducting a dedicated DDI study with ARAs. Thus, relationship between 
Cmax or AUC ratios and dose number was investigated (Figure 7). The AUC and Cmax 
ratios were decreased with the increasing dose number and the relationship was 
described by negative log-linear regression with R2 values of 0.47 and 0.56, 
respectively. 
Similar to the previous research, approximately 50% of the results from this study (14 
out of 29 for AUC and 10 out of 29 for Cmax) were false positives when DDI positive 
is defined as values with more than 50% of decrease of AUC or Cmax. 
 
Relationship between Cmax or AUC ratios and solubility ratios (acidic/neutral pH) 
The relationship between Cmax or AUC ratios and solubility ratios (at acidic pH/at 
neutral pH) were investigated (Figure 8). The AUC and Cmax ratios were decreased 
with the increasing solubility ratios and the relationship was well characterized by 
negative log-linear regression with R2 values of 0.77 and 0.76, respectively. Drug 
exposure under the condition of being co-administered with ARAs seemed to be 
decreased by approximately 40%-50% as compared to that without ARAs when the 
solubility ratio is greater than 1000. 
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Figure 6  Selection of clinical data for this study 
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Table 3  List of test drugs with dose number (D0), solubility ratio (acidic/neutral pH), type of ARA, Cmax or AUC ratio% (with/without 
ARA) 
Compound 
Name; 
[acidity] 
Dose 
(mg) 
Solubility; [Source] D0 at neutral 
pH 
Solubility ratio 
(acidic/neutral 
pH) 
pKa BCS 
class 
ARA 
(1=PPI, 
2=H2B) 
Cmax 
ratio% 
(w /wo 
ARA) 
AUC 
ratio% 
(w/wo 
ARA) 
Alogliptin; 
[basic] 
100 51.9 mg/mL (0.1N HCl), 21.3 
mg/mL (pH 7);  [Alogliptin 
J-IF] 
0.0188 2 8.5 I 2 105 107 
ARRY-403; 
[basic] 
100 1.8 mg/mL (pH 2), 0.007 
mg/mL (pH 6.3); [29] 
229 257 3.9, 9.8 II 2 66 73 
Atazanavir; 
[basic] 
300 5.2 mg/mL (pH 1.9), 0.002 
mg/mL (pH 5.4 and pH 8.7); 
[Atazanavir J-IF] 
600 2600 4.7 II 1 32 31 
Atazanavir 300 -  600 2600 - - 2 63 65 
Axitinib; 
[basic] 
100 0.075 mg/mL (pH 2.2), 
0.0002 mg/mL (pH 6.0); 
[FDA review report 2.5.1] 
2000 375 4.8 II 1 58 85 
Bosutinib; 
[basic] 
400 9.4 mg/mL (pH 2), 0.02 
mg/mL (pH 6.8); [FDA 
review report 2.5.1] 
8 470 7.9 IV 1 54 74 
Clopidogrel; 
[basic] 
75 694.5 mg/mL (pH 1.2), 12.8 
mg/mL (pH 6.8); [30] 
0.0234 54 4.5 II 1 72 88 
Clopidogrel 600 -  0.188 54 - - 2 90 93 
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Compound 
Name; 
[acidity] 
Dose 
(mg) 
Solubility; [Source] D0 at neutral 
pH 
Solubility ratio 
(acidic/neutral 
pH) 
pKa BCS 
class 
ARA 
(1=PPI, 
2=H2B) 
Cmax 
ratio% 
(w /wo 
ARA) 
AUC 
ratio% 
(w/wo 
ARA) 
Cobimetinib; 
[basic] 
20 2.71 mg/mL (pH 2), 0.55 
mg/mL (pH 7.5); [31] 
0.145 5 8.85 NA 1 100 111 
Dasatinib; 
[basic] 
50 18.4 mg/mL (pH 2.6), 0.008 
mg/mL (pH 6.0); [EMEA 
review report 2006] 
25 2300 3.1, 
6.8, 
10.8 
II 1 58 57 
Dasatinib 50 - 25 2300 - - 2 37 40 
Domperidone
; [basic] 
10 0.5668 mg/mL (pH 1.0), 
0.2433 mg/mL (pH 5); [32] 
0.1644 2 7.9 II 1 84 93 
Gabapentin; 
[zwitterionic] 
1200 Freely soluble in water and 
both basic and acidic aqueous 
solutions; [USPI] 
0.048 
(estimated as 
100 mg/mL 
based on 
freely soluble) 
1 3.68 
(acid), 
10.70 
(base) 
III 2 96 99 
GDC-0941; 
[basic] 
40 0.75 mg/mL (pH 1), <0.001 
mg/mL (pH6.8); [33] 
160 750 1.54, 
4.24 
II 1 31 46 
Gefitinib; 
[basic] 
250 21 mg/mL (pH 1.0), <0.001 
mg/mL (pH 7); [2012 Budha 
NR] 
1000 21000 5.4, 7.2 II 2 30 56 
GSK1322322
; [unknown] 
1000 1 mg/mL (pH 7); [34] 4 NA NA NA 2 42 62 
GSK1349572
; [unknown]  
50 Solubility does not change 
over the physiological pH 
NA 1 NA II 1 92 100 
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Compound 
Name; 
[acidity] 
Dose 
(mg) 
Solubility; [Source] D0 at neutral 
pH 
Solubility ratio 
(acidic/neutral 
pH) 
pKa BCS 
class 
ARA 
(1=PPI, 
2=H2B) 
Cmax 
ratio% 
(w /wo 
ARA) 
AUC 
ratio% 
(w/wo 
ARA) 
range; [27] 
Imatinib; 
[basic] 
400 Freely soluble (100-1,000 
mg/mL) up to pH 5.5; [23] 
0.016 1 7.7 NA 1 97 107 
Indinavir; 
[basic] 
800 >100 mg/mL (pH 3.0), <0.03 
mg/mL (pH 6.0); [35] 
107 3333 6.2 IV or II 1 59 53 
Itraconazole; 
[basic] 
200 0.004 mg/mL (pH 1), 
0.000001 mg/mL (neutral 
pH); [36] 
800000 4000 3.7 II 2 47 49 
Lapatinib; 
[basic] 
1250 0.001 mg/mL (pH 1), 
0.000005 mg/mL (pH 6); 
[Lapatinib J-IF] 
1000000 200 NA II 1  74 
Mycophenola
-te mofetil; 
[basic] 
2200 4.075 mg/mL (pH 2), 0.04 
mg/mL (pH 7.0); [37] 
220 102 5.6, 8.5 II 1 69 75 
Nilotinib; 
[basic] 
400 Slightly soluble (1-10 
mg/mL) at pH 1.0, very 
slightly soluble (0.1-1 
mg/mL) at pH 2.0 and pH 
3.0, and practically insoluble 
(<0.1 mg/mL) in buffer 
solutions of pH ≥ 4.5; [23] 
16 100 2.1, 5.4 IV 1 73 66 
Nilotinib 400 - 16 100 - - 2 97 91 
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Compound 
Name; 
[acidity] 
Dose 
(mg) 
Solubility; [Source] D0 at neutral 
pH 
Solubility ratio 
(acidic/neutral 
pH) 
pKa BCS 
class 
ARA 
(1=PPI, 
2=H2B) 
Cmax 
ratio% 
(w /wo 
ARA) 
AUC 
ratio% 
(w/wo 
ARA) 
Posaconazole
; [basic] 
400 617 mg/mL (pH 1.2), 5.61 
mg/mL (pH 6.5); estimated 
graphical data from [38] 
7.13 110 3.6, 4.6 II 1 54 68 
Posaconazole 200  - 0.143 110 - - 2 61 61 
Revexepride; 
[basic] 
1 High solubility across the 
gastric pH range, so an effect 
on its PK due to a change in 
gastric pH is unlikely; [28] 
NA 1 NA NA 1 103 104 
Saxagliptin; 
[basic] 
5 103.5 mg/mL (pH 0.7), 149.2 
mg/mL (pH 5.9); [FDA 
review report] 
0.000426 0.69 7.3 III 1 98 113 
Saxagliptin 5 - 0.000426 0.69 - - 2 114 103 
Vardenafil; 
[basic] 
10 26 mg/mL (0.01 N HCl), 0.31 
mg/mL (pH 6); [Vardenafil 
J-IF] 
0.129 84 8.8 II 2 94 97 
ARA: acid-reducing agent, PPI: proton pump inhibitor, H2B: H2 blocker, BCS: Biopharmaceutics Classification System, J-IF: Japanese interview form, 
USPI: US package insert 
NA: not assessed 
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<Logarithmic scale> 
a) D0 and AUC ratio% b) D0 and Cmax ratio% 
 
<Normal scale (dose number up to 2000)> 
a) D0 and AUC ratio% b) D0 and Cmax ratio% 
   
Figure 7  Relationship between dose number at neutral pH and AUC or Cmax 
ratio% (with/without ARA) 
Open circle (○, N=27) and diamonds (◊, N=26) represents AUC and Cmax ratio% 
(with/without ARA), respectively. 
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<Logarithmic scale> 
a) Solubility ratio and AUC ratio% b) Solubility ratio and Cmax ratio% 
 
<Normal scale (ratio of solubility up to 5000)> 
a) Solubility ratio and AUC ratio% b) Solubility ratio and Cmax ratio% 
  
Figure 8  Relationship between solubility ratio (acidic/neutral pH) and AUC or 
Cmax ratio% (with/without ARA) 
Open circle (○, N=28) and diamonds (◊, N=27) represents AUC and Cmax ratio% 
(with/without ARA), respectively. 
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3.4. Discussion 
Orally-administered drug products must undergo dissolution in the gastrointestinal (GI) 
tract before they can be absorbed [39]. In general, the dissolution rate (DR) is described 
with the following modification of the Noyes-Whitney equation [39, 40, 41]: DR = dmdt = D ∙ SV ∙ h (Cs − Ct) 
The dissolution rate (DR, dm/dt) is a function of the diffusion coefficient of the drug 
(D), the surface area of the drug (S), the effective (hydrodynamic) boundary layer 
thickness (h), the saturation solubility of the drug molecule (Cs), the concentration of 
the dissolved solute (Ct) and the volume of the dissolution medium (V). Highly 
permeable drugs like BCS class 1 and 2 would be absorbed quickly and therefore their 
concentrations of the dissolved solute (i.e. Ct) would stay low. 
The pH of the GI fluids in the GI tract influences the dissolution rate of a drug. The pH 
influences the solubility of either acidic or basic drug, since ionized drugs tend to 
exhibit much greater aqueous solubility than unionized counterpart. Weakly basic drugs 
tend to have a slower dissolution rate at higher pH, whereas weakly acidic drugs 
dissolve faster at higher pH [39, 41]. 
In the previous research by Zhang et al. [20], dose number at neutral pH was used for 
the selection of drugs that gastric pH elevation potentially affects their drug exposure. 
That is, if the dose number for a test drug is larger than 1 and the test drug is a basic 
compound exhibiting pH-dependent solubility, there is a possibility that the drug 
exposure is decreased when it is co-administered with ARAs. However, the R2 values 
for dose number (0.47 and 0.56) were smaller than those with solubility ratios of acidic 
pH to neutral pH (0.77 and 0.76). Solubility values at neutral and acidic pH would 
reflect the drug amount dissolved in the GI tract following oral administration with or 
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without ARAs, respectively. Therefore, the drug exposure ratios (with/without ARAs) 
would be related to the solubility ratios (acidic/neutral pH). Based on these results, the 
solubility ratios at acidic and neutral pH were more appropriate for predicting the effect 
of ARAs on drug exposure than dose number at neutral pH.  
Tsume et al. [42] and Matsui et al. [43] developed multi-compartmental in vitro 
dissolution apparatus, Gastrointestinal Simulator (GIS) to predict in vivo dissolution 
from stomach to small intestine. They investigated the in vivo dissolution for dasatinib, 
fluconazole and dipyridamole under normal (pH 2.0) and elevated gastric pH (pH 6.0) 
by using GIS. The PK simulation results by GastroPlusTM software (Simulations Plus, 
Inc.) and the reduction ratios calculated by dissolved amount in GIS seemed to 
generally predict clinical DDI results with ARAs. However, this prediction would be 
time-consuming, because dissolution experiment with GIS system, measurement of 
drug concentrations and in silico simulation are required. Thus, for an early decision 
making of necessity and timing of a dedicated DDI study with ARAs, our simple 
prediction would be better, because only in vitro solubility data are required for 
estimating the effect of ARAs on drug exposure. 
In drug development, it is important to identify factors affecting drug exposure. Since 
those factors have the potential to affect drug exposure, it may cause large inter-subject 
and intra-subject variability of drug exposure. Consequently, the variability makes study 
results of efficacy and safety complicated. Depending on exposure-response 
relationships for a test drug, drug companies have to consider setting dose modification 
rules in pivotal clinical trials and/or to prohibit co-administered drugs to secure efficacy 
and safety of patients. Also, assessment of those factors and description of the 
precaution in package insert would be required for appropriate use in clinical practice. 
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Thus, it is important to know factors affecting drug exposure in early stage of drug 
development.  
Based on our finding, it is better to assess in vitro solubility values at both acidic and 
neutral pH and predict the effect of ARAs on drug exposure. With consideration for 
exposure-response relationship for a test drug, expected effect of ARAs on drug 
exposure, and prevalence of ARAs in the target disease, it is recommended to consider 
the necessity and timing of conducting a dedicated DDI study with ARAs. Although 
data used for this study is limited, drug exposure under the condition of being 
co-administered with ARAs is thought to be decreased by approximately 40%-50% as 
compared to that without ARAs when the solubility ratio is greater than 1000. Although 
it depends on the exposure-response relationships for the test drug, increase of dose 
level (e.g. 2-folds) may need to be considered to maintain efficacy by adjusting drug 
exposure.    
In this research, solubility data of drugs at acidic and neutral pH available to the public 
were limited, although there were approximately 100 clinical DDI study data with 
ARAs. Also the pH values used for the assessment varied within a limited range among 
the test drugs due to limitation of available solubility data. In addition, although we 
excluded DDI study results investigating interaction between ARAs and test drugs via 
CYP enzymes and transporters, there might be unknown clearance mechanisms through 
CYP enzymes and transporters for the test drugs, and the interactions of metabolism and 
transporter might be included in the net effect of ARAs on drug exposure. Further 
investigation would be desirable to confirm the results from this research. 
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4. Overall discussion 
 
Based on the research regarding factors affecting intra-subject variability, absolute oral 
BA was shown to be one of the major factors to predict the extent of intra-subject CV of 
drug exposure. Taking different strategies based on the absolute oral BA value is 
thought to be efficient. When absolute oral BA is less than 5%, the intra-subject 
variability is predicted to be greater than 30%. In this case, it is better to plan replicate 
crossover design and two-stage BE to mitigate the risk of BE failure. When absolute 
oral BA is greater than 80%, the intra-subject variability is predicted to be less than 20%. 
In the first BE study, intra-subject variability for a test drug is usually unknown. 
However, it would be efficient to estimate sample size assuming the intra-subject 
variability to be 20% for those drugs, instead of conducting a pilot BE study to know 
the intra-subject variability. 
Acidic nature of drugs is also identified as an additional factor increasing intra-subject 
variability of Cmax as compared to AUC. Thus, when planning a BE study, it would be 
desirable to check whether a test drug is acidic compound with pKa less than 6. 
Considering these factors in drug development would be useful to mitigate risk of BE 
failure and lead to efficient drug development. 
There is a possibility that ARAs affect drug exposure for orally-administered drugs 
having pH dependent solubility. Based on our research, solubility ratio of acidic pH to 
neutral pH is a potential factor relating to effect of ARA on drug exposure. Although the 
number of test drugs is limited, if the solubility ratio is greater than 1000, the effect of 
ARA on drug exposure is predicted to be about 40%-50%. For maintaining efficacy by 
adjusting drug exposure, increase of dose level (e.g. 2-folds) may need to be considered. 
Thus, investigating in vitro solubility at acidic and neutral pH is proposed in early stage 
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of drug development. If the solubility ratio is greater than 1000, it is recommended to 
conduct a dedicated DDI study with ARA in early stage of clinical development. If the 
solubility ratio is less than 10, the effect of ARA on drug exposure is predicted to be less 
than 10%. Thus, no dedicated DDI study with ARA is recommended. For other drugs of 
which solubility ratio ranges from 10 to 1000, necessity of conducting a dedicated DDI 
study with ARA would depend on exposure-response relationships for the test drug as 
well as the frequency of concomitant use of ARAs in the target disease. If the test drug 
has narrow therapeutic window, it is better to know the effect of ARA on drug exposure 
by conducting a dedicated DDI study or explore the effect by performing population PK 
analysis based on the information about co-administered drugs in clinical studies. 
Based on this research, we found factors affecting drug exposure in BE studies and DDI 
studies with ARAs. Knowledge of these factors before conducting those clinical studies 
must be useful for establishing an appropriate study design, mitigating a risk of study 
failure, and judging the necessity and timing of such clinical studies. Thus, our findings 
will contribute to efficient clinical development of orally-administered drugs in the 
future. 
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5. Conclusion 
 
Investigation of factors shown in this study (absolute bioavailability, acidic nature, and 
in vitro solubility) would help to predict the magnitude of effect on drug exposure. 
Since it leads to mitigating risk of BE failure, establishing an appropriate study design 
for BE studies and judging the necessity and timing of a DDI study with ARAs, our 
findings will contribute to efficient development of orally-administered drugs in the 
future. 
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